Free Trial
NASDAQ:SCNI

Scinai Immunotherapeutics Q1 2024 Earnings Report

Scinai Immunotherapeutics logo
$1.40 -0.06 (-4.11%)
Closing price 10/17/2025 03:59 PM Eastern
Extended Trading
$1.40 0.00 (-0.29%)
As of 10/17/2025 07:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Scinai Immunotherapeutics EPS Results

Actual EPS
-$4.00
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Scinai Immunotherapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Scinai Immunotherapeutics Announcement Details

Quarter
Q1 2024
Time
N/A
Conference Call Date
Tuesday, July 2, 2024
Conference Call Time
7:00AM ET

Upcoming Earnings

Scinai Immunotherapeutics' Q3 2025 earnings is scheduled for Sunday, November 2, 2025

Earnings Documents

Scinai Immunotherapeutics Earnings Headlines

REVEALED: Something Big Happening Behind White House Doors
What I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for yourself. Once you see what’s unfolding behind the scenes, you’ll understand why I rushed this interview and opportunity to you today.tc pixel
See More Scinai Immunotherapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Scinai Immunotherapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Scinai Immunotherapeutics and other key companies, straight to your email.

About Scinai Immunotherapeutics

Scinai Immunotherapeutics (NASDAQ:SCNI) Inc is a clinical-stage biotechnology company dedicated to developing novel small-molecule therapies that enhance the immune system’s capacity to recognize and destroy cancer cells. The company’s research emphasizes checkpoint modulation and the discovery of compounds designed to work in concert with established immuno-oncology treatments across a range of solid tumors.

Scinai’s pipeline comprises preclinical and early-stage candidates, and the company relies on collaborations with academic institutions and contract research organizations to advance its discovery and development efforts. These partnerships support lead optimization, biomarker identification and the generation of preclinical efficacy and safety data in preparation for eventual clinical evaluation.

Headquartered in the United States, Scinai Immunotherapeutics conducts its research and development activities primarily in North America while pursuing strategic alliances to extend its presence into European and Asian markets. The company remains focused on translating its scientific platform into robust therapeutic options, underpinned by rigorous preclinical validation and translational research initiatives.

View Scinai Immunotherapeutics Profile

More Earnings Resources from MarketBeat